undamentalytics Newsletter
Sign in

Inmed Pharmaceuticals Inc. key statistics and ratios

In fiscal 2025, Inmed Pharmaceuticals Inc. had return on equity of -15.0% and a net margin of -34.4%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Jun 20212022Jun 20222023Jun 20232024Jun 20242025Jun 2025LTMDec 2025
Net margin−535.9%<−999%−192.2%−166.9%−34.4%−26.7%
Return on equity−138.3%—−75.1%−72.1%−15.0%−10.4%
Return on assets−104.3%−164.8%−59.1%−59.2%−12.4%−9.0%
R&D as % of revenue280.4%668.5%90.2%70.0%57.1%49.0%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

0 of 0 checks passed · September 30, 2026
  • Short-term assets cover short-term liabilities The company doesn't report a short-term split. Not assessable.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Inmed Pharmaceuticals Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ENSC vs INMINM vs OCGNINM vs TRDA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inmed Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inmed Pharmaceuticals Inc.